Overview

Surgical Pembro +/- Olaparib w TMZ for rGBM

Status:
Not yet recruiting
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
This research study is studying a combination therapy as a possible treatment for recurrent glioblastoma (GBM), a brain tumor that is growing or progressing despite earlier treatment. The names of the study interventions involved in this study are/is: - Pembrolizumab - Olaparib - Temozolomide (Temodar)
Phase:
Phase 2
Details
Lead Sponsor:
L. Nicolas Gonzalez Castro, MD, PhD
Collaborator:
Merck Sharp & Dohme LLC
Treatments:
Olaparib
Pembrolizumab
Temozolomide